The global Rheumatoid Arthritis (RA) market is anticipated to grow owing to its rising prevalence across the globe, and continuous research and development for finding effective combination drugs for treating Rheumatoid Arthritis (RA).
Rheumatoid Arthritis is an autoimmune disorder or a chronic inflammatory disorder that affects individual’s joints. In some cases, this disorder can damage the skin, eyes, blood vessels, lungs, and heart. Usually, RA damages both side of the body i.e. if one side arm or leg is affected with RA than there are chances for other side to be affected too. Rheumatoid arthritis is caused when the immune system attacks the body tissues known as synovium, and affects the lining of the joints. This causes painful swelling that results into bone erosion and joint deformities.
Rheumatoid arthritis not only affects the joints but also has its effect on the non-joint structure of the body that includes; skin, lungs, eyes, kidney, nerve tissue, bone marrow, and blood vessel. Major risk factors that influence rheumatoid arthritis are sex, age, smoking, obesity, genetics, and environmental exposures. On the other hand, RA increases the risk of osteoporosis, dry eyes and mouth, carpal tunnel syndrome, heart problems, and infections.
Rheumatoid arthritis is majorly characterised by symptoms such as, joint pain, joint swelling, loss of joint function, fatigue, fever, weight loss and joint stiffness. Early diagnosis of rheumatoid arthritis helps the doctor in better treatment. However, diagnosis of RA is not that easy it requires several lab test and confirm clinical examination.
Rising awareness about rheumatoid arthritis, and increasing launch of various generic and novel treatments of rheumatoid arthritis are factors to support the growth of global rheumatoid arthritis market.
The global rheumatoid arthritis market is primarily driven by factors such as increasing number of patients suffering from rheumatoid arthritis, and increasing governments efforts for easy drug availability that act effectively for treating RA. Moreover, increasing acceptances for the drugs manufactured by the biopharmaceutical companies and presence of well-defined regulatory policies would also surge the rheumatoid arthritis market during the forecast period. Furthermore, increasing launches of novel biologic drugs and penetration of generic drugs also positively affects the growth of rheumatoid arthritis market. Therefore, rheumatoid arthritis market is noticing a shift in the form traditional treatment options to the combination drugs.
The global rheumatoid arthritis market is segmented on the basis of drug type, sales channel, and geography.
On the basis of drug type, rheumatoid arthritis market is segmented into:
Geographically, the global rheumatoid arthritis market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Rising need for effective treatment and diagnosis of rheumatoid arthritis, and sophisticated healthcare infrastructure to lead the rheumatoid arthritis market in North America region.
North America is expected to dominate the global rheumatoid arthritis market over the forecast period. The major factors driving the growth of this market in North America are increasing patient awareness for various technological advancements, and rising R&D expenditure by the biopharmaceutical companies. Additionally, the increased governments initiatives for promoting research and development for developing biologic combination drugs would influence the growth of global rheumatoid arthritis market. Moreover, high quality healthcare facility in the U.S., increasing number of patients suffering from RA would add up a significant growth to this market. Also, strong reimbursement policies by the local governments would also boost the rheumatoid arthritis market during the forecast period.
However, Asia Pacific is expected to grow rapidly during forecast period. Increasing awareness about rheumatoid arthritis, government initiative for promoting the use of combination drugs as an effective treatment, and increased preference for cost-effective generic drugs in the developing countries to govern the global rheumatoid arthritis market during upcoming years.